Do analysts rate NSPR or QNRX?

InspireMD currently has a consensus price target of $4.50, indicating a potential upside of 525.87%. Given InspireMD's stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to MLSS or QNRX?

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Milestone Scientific. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 2 mentions for Milestone Scientific. Quoin Pharmaceuticals' average media sentiment score of 0.22 beat Milestone Scientific's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Scientific 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PETV or QNRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor PETV or QNRX?

In the previous week, Quoin Pharmaceuticals had 3 more articles in the media than PetVivo. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 1 mentions for PetVivo. Quoin Pharmaceuticals' average media sentiment score of 0.22 beat PetVivo's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PSTV or QNRX?

Plus Therapeutics currently has a consensus price target of $56.40, indicating a potential upside of 1,252.52%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Plus Therapeutics is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to PSTV or QNRX?

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 3 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.62 beat Quoin Pharmaceuticals' score of 0.22 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate QNRX or NMTC?

NeuroOne Medical Technologies has a consensus price target of $11.67, indicating a potential upside of 338.60%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NeuroOne Medical Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Quoin Pharmaceuticals (QNRX) Competitors

$4.23 -0.22 (-4.94%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$4.22 -0.01 (-0.24%)

As of 07:55 AM Eastern

Compare

QNRX vs. NSPR, MLSS, PETV, PSTV, and NMTC

Should you buy Quoin Pharmaceuticals stock or one of its competitors? MarketBeat compares Quoin Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quoin Pharmaceuticals include InspireMD (NSPR), Milestone Scientific (MLSS), PetVivo (PETV), Plus Therapeutics (PSTV), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "medical equipment" industry.

How does Quoin Pharmaceuticals compare to InspireMD?

InspireMD (NYSE:NSPR) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

In the previous week, Quoin Pharmaceuticals had 4 more articles in the media than InspireMD. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 0 mentions for InspireMD. Quoin Pharmaceuticals' average media sentiment score of 0.22 beat InspireMD's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
InspireMD	Neutral
Quoin Pharmaceuticals	Neutral

InspireMD currently has a consensus price target of $4.50, indicating a potential upside of 525.87%. Given InspireMD's stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 34.1% of InspireMD shares are owned by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Quoin Pharmaceuticals has lower revenue, but higher earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.85M	3.10	-$19.92M	-$0.73	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

InspireMD has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Quoin Pharmaceuticals has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Summary

InspireMD beats Quoin Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Milestone Scientific presently has a consensus target price of $1.00, suggesting a potential upside of 153.49%. Given Milestone Scientific's stronger consensus rating and higher possible upside, equities research analysts plainly believe Milestone Scientific is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quoin Pharmaceuticals has a net margin of 0.00% compared to Milestone Scientific's net margin of -52.01%. Milestone Scientific's return on equity of -60.26% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Scientific	-52.01%	-60.26%	-40.23%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Milestone Scientific has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Milestone Scientific has higher revenue and earnings than Quoin Pharmaceuticals. Milestone Scientific is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Scientific	$8.90M	3.92	-$6.93M	-$0.05	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Milestone Scientific. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 2 mentions for Milestone Scientific. Quoin Pharmaceuticals' average media sentiment score of 0.22 beat Milestone Scientific's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Scientific	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 9.2% of Milestone Scientific shares are held by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Milestone Scientific and Quoin Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to PetVivo?

PetVivo (NASDAQ:PETV) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Quoin Pharmaceuticals has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Quoin Pharmaceuticals' return on equity of -489.85% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

PetVivo has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

In the previous week, Quoin Pharmaceuticals had 3 more articles in the media than PetVivo. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 1 mentions for PetVivo. Quoin Pharmaceuticals' average media sentiment score of 0.22 beat PetVivo's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 10.8% of PetVivo shares are owned by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

PetVivo has higher revenue and earnings than Quoin Pharmaceuticals. PetVivo is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	27.31	-$10.95M	-$0.38	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Quoin Pharmaceuticals beats PetVivo on 10 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Plus Therapeutics currently has a consensus price target of $56.40, indicating a potential upside of 1,252.52%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Plus Therapeutics is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 3 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.62 beat Quoin Pharmaceuticals' score of 0.22 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Plus Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Quoin Pharmaceuticals has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.51	-$22.39M	-$2.30	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Summary

Plus Therapeutics beats Quoin Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Quoin Pharmaceuticals (NASDAQ:QNRX) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

NeuroOne Medical Technologies has higher revenue and earnings than Quoin Pharmaceuticals. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
NeuroOne Medical Technologies	$12.10M	1.91	-$3.61M	-$0.85	N/A

Quoin Pharmaceuticals has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -99.43% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%

Quoin Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.94 beat Quoin Pharmaceuticals' score of 0.22 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroOne Medical Technologies has a consensus price target of $11.67, indicating a potential upside of 338.60%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

NeuroOne Medical Technologies beats Quoin Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Quoin Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNRX vs. The Competition

Export

Metric	Quoin Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.94M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-0.14	19.17	27.12	24.26
Price / Sales	N/A	838.79	587.25	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	0.27	4.22	10.89	6.29
Net Income	-$15.81M	$64.26M	$3.58B	$330.66M
7 Day Performance	-11.88%	-3.58%	-2.11%	-1.35%
1 Month Performance	0.71%	2.12%	3.28%	-0.64%
1 Year Performance	-53.26%	20.35%	26.33%	19.08%

Quoin Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNRX Quoin Pharmaceuticals	0.7983 of 5 stars	$4.23 -4.9%	N/A	-52.4%	$8.94M	N/A	N/A	4	Short Interest Increase
NSPR InspireMD	3.3619 of 5 stars	$0.70 -2.3%	$4.50 +541.9%	-69.5%	$32.83M	$10.85M	N/A	50
MLSS Milestone Scientific	1.1347 of 5 stars	$0.34 -0.4%	$1.00 +197.6%	-40.8%	$29.72M	$8.90M	N/A	30
PETV PetVivo	N/A	$0.79 -3.7%	N/A	-3.8%	$29.66M	$1.05M	N/A	20
PSTV Plus Therapeutics	2.5323 of 5 stars	$3.84 -2.1%	$56.40 +1,369.1%	-53.6%	$26.28M	$5.21M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNRX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. NSPR, MLSS, PETV, PSTV, and NMTC

How does Quoin Pharmaceuticals compare to InspireMD?

Summary

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Summary

How does Quoin Pharmaceuticals compare to PetVivo?

Summary

How does Quoin Pharmaceuticals compare to Plus Therapeutics?

Summary

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. NSPR, MLSS, PETV, PSTV, and NMTC

How does Quoin Pharmaceuticals compare to InspireMD?

Does the media refer more to NSPR or QNRX?

Do analysts rate NSPR or QNRX?

Do insiders & institutionals have more ownership in NSPR or QNRX?

Which has preferable earnings & valuation, NSPR or QNRX?

Which has more volatility and risk, NSPR or QNRX?

Is NSPR or QNRX more profitable?

Summary

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Do analysts rate MLSS or QNRX?

Is MLSS or QNRX more profitable?

Which has more volatility & risk, MLSS or QNRX?

Which has better valuation and earnings, MLSS or QNRX?

Does the media refer more to MLSS or QNRX?

Do insiders and institutionals believe in MLSS or QNRX?

Summary

How does Quoin Pharmaceuticals compare to PetVivo?

Is PETV or QNRX more profitable?

Which has more volatility and risk, PETV or QNRX?

Does the media favor PETV or QNRX?

Do institutionals and insiders hold more shares of PETV or QNRX?

Which has stronger valuation and earnings, PETV or QNRX?

Do analysts recommend PETV or QNRX?

Summary

How does Quoin Pharmaceuticals compare to Plus Therapeutics?

Do institutionals and insiders have more ownership in PSTV or QNRX?

Is PSTV or QNRX more profitable?

Do analysts recommend PSTV or QNRX?

Does the media refer more to PSTV or QNRX?

Which has more volatility and risk, PSTV or QNRX?

Which has stronger earnings and valuation, PSTV or QNRX?

Summary

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Which has better valuation & earnings, QNRX or NMTC?

Is QNRX or NMTC more profitable?

Which has more risk & volatility, QNRX or NMTC?

Do institutionals and insiders believe in QNRX or NMTC?

Does the media refer more to QNRX or NMTC?

Do analysts rate QNRX or NMTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools